by Lisa Nadal | Nov 11, 2022 | 2022, Past Events, Scientific
The study describes the discovery of GCPIII as the protein responsible for the accumulation of conventional PSMA targeting agents in healthy organs. More detailsby Lisa Nadal | Nov 7, 2022 | 2022, Press Releases, Scientific
Philogen announces publication in Chem (Cell Press) on novel affinity matured OncoFAP ligands isolated from DNA-Encoded Chemical Libraries. The novel OncoFAP ligands show a prolonged residence time in Fibroblast Activation Protein (FAP) positive tumors. The...by Lisa Nadal | Oct 19, 2022 | 2022, Press Releases, Scientific
The study shows excellent tumor uptake of the novel OncoFAP-MMAE Small Molecule-Drug Conjugates (SMDCs) with high and selective release of the cytotoxic MMAE payload at the tumor site. OncoFAP-based pro-drugs are currently being developed for the imaging and therapy...by Lisa Nadal | Sep 15, 2022 | 2022, Press Releases, Scientific
The study shows selective tumor uptake of IL12-7NP2 and potent antitumor activity as single agent and in combination with immune checkpoint inhibitors. The product is well tolerated when administered to non-human primates. More detailsby m.romi | Jul 25, 2022 | 2022, Press Releases, Scientific
More detailsby Lisa Nadal | Jun 27, 2022 | 2022, Past Events, Scientific
Philogen will attend the 3rd Annual Cytokine-Based Drug Development Summit in Boston. Roberto De Luca, Head of Antibody Therapeutics, will give a virtual lecture entitled “Antibody-cytokine fusion proteins against Fibroblast Activation Protein (FAP)” on the 28...
Recent Comments